JP2004519469A - 多発性硬化症を処置するための医薬組成物 - Google Patents

多発性硬化症を処置するための医薬組成物 Download PDF

Info

Publication number
JP2004519469A
JP2004519469A JP2002562339A JP2002562339A JP2004519469A JP 2004519469 A JP2004519469 A JP 2004519469A JP 2002562339 A JP2002562339 A JP 2002562339A JP 2002562339 A JP2002562339 A JP 2002562339A JP 2004519469 A JP2004519469 A JP 2004519469A
Authority
JP
Japan
Prior art keywords
thien
hydroxy
benzo
use according
ylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002562339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004519469A5 (enExample
Inventor
ノイ，インゴ・エス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2004519469A publication Critical patent/JP2004519469A/ja
Publication of JP2004519469A5 publication Critical patent/JP2004519469A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002562339A 2001-01-26 2002-01-23 多発性硬化症を処置するための医薬組成物 Pending JP2004519469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10103506A DE10103506A1 (de) 2001-01-26 2001-01-26 Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose
PCT/EP2002/000653 WO2002062332A1 (de) 2001-01-26 2002-01-23 Pharmazeutische zusammensetzung zur behandlung von multiple sklerose

Publications (2)

Publication Number Publication Date
JP2004519469A true JP2004519469A (ja) 2004-07-02
JP2004519469A5 JP2004519469A5 (enExample) 2005-06-09

Family

ID=7671836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002562339A Pending JP2004519469A (ja) 2001-01-26 2002-01-23 多発性硬化症を処置するための医薬組成物

Country Status (5)

Country Link
US (1) US20050020665A1 (enExample)
EP (1) EP1363618B1 (enExample)
JP (1) JP2004519469A (enExample)
DE (2) DE10103506A1 (enExample)
WO (1) WO2002062332A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168015A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264456A (ja) * 1987-02-10 1988-11-01 アボット・ラボラトリーズ インドール、ベンゾフラン、ベンゾチオフェン含有リポキシゲナーゼ抑制化合物
JPH0641104A (ja) * 1991-07-30 1994-02-15 Ciba Geigy Ag ヘテロアリール基により置換されたヒドロキシルアミン誘導体
WO1998020864A2 (en) * 1996-11-13 1998-05-22 Universita' Degli Studi Di Brescia - Dipartimento Di Scienze Biomediche Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5093356A (en) * 1990-01-16 1992-03-03 Merck Frosst Canada, Inc. Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264456A (ja) * 1987-02-10 1988-11-01 アボット・ラボラトリーズ インドール、ベンゾフラン、ベンゾチオフェン含有リポキシゲナーゼ抑制化合物
JPH0641104A (ja) * 1991-07-30 1994-02-15 Ciba Geigy Ag ヘテロアリール基により置換されたヒドロキシルアミン誘導体
WO1998020864A2 (en) * 1996-11-13 1998-05-22 Universita' Degli Studi Di Brescia - Dipartimento Di Scienze Biomediche Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTA NEUROLOGICA SCANDINAVICA (1989), 79(3), 223-226, JPN6008029047, ISSN: 0001065498 *
ACTA NEUROLOGICA SCANDINAVICA (1990), 81(3), 237-238, JPN6008029045, ISSN: 0001065497 *
NEUROLOGY (1998), 51(5), 1342-1352, JPN6008029044, ISSN: 0001065496 *

Also Published As

Publication number Publication date
WO2002062332A1 (de) 2002-08-15
EP1363618A1 (de) 2003-11-26
DE10103506A1 (de) 2002-08-14
EP1363618B1 (de) 2006-05-03
DE50206657D1 (de) 2006-06-08
US20050020665A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
EP1363618B1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
JP2025118786A (ja) 安定なカンナビノイド製剤
EP1477166B1 (de) Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
EP3741747B1 (en) Method for preventing and/or treating anxiety
JPS62249923A (ja) パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法
LÉAN et al. Beneficial effects of serotonin precursors in postanoxic action myoclonus
JP6803898B2 (ja) オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ
JP2002527474A (ja) 躁病および双極性障害の治療法
CA2215923C (en) A method of treatment of mania and bipolar disorder
JP2002518442A (ja) 偏頭痛及び情動病の治療及び予防用バルプロ酸類似物の用法
WO2022087176A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
JP2021165304A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
WO2007054348A1 (de) Neue arzneimittel
JPH06500537A (ja) アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用
JPH03170475A (ja) 抑うつ症治療剤
JPS59116216A (ja) アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤
JP3142559B2 (ja) 止痒剤としての血小板活性化因子拮抗剤の用途
JP2003530350A (ja) 外傷性脳損傷及びその他のニューロン障害治療用医薬
JP7257091B2 (ja) 認知症の治療及び予防薬
JPWO2019221114A1 (ja) ベタニンまたはその類似化合物を含む皮膚組織修復剤
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
HK40041872A (en) Method for preventing and/or treating aging-associated cognitive impairment
HK1086500A (en) Use of a topical medicament comprising riluzole
BR112018012195B1 (pt) Uso de 2-[4-(1,1-dimetiletil)fenil]-1h-benzimidazol, ou um sal farmaceuticamente aceitável do mesmo
HK1261918B (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081125